Fluid decreased in vein occlusion, AMD, and DME on aflibercept 8 mg or faricimab
News|Articles|October 23, 2026
Osmoprotection for a more stable tear film in moderate-to-severe dry eye disease
Artelac Ectoin improved tear-film stability and key dry-eye symptoms within 28 days
Advertisement
Advertorial:
Artelac Ectoin improved tear-film stability and key dry-eye symptoms within 28 days. Hyperosmolar stress contributes to tear-film instability, ocular-surface damage and inflammatory signalling in dry eye disease. Artelac Ectoin combines 2% ectoine with 0.24% sodium hyaluronate, bringing osmoprotection and lubrication together in one preservative-free drop.1–4
Advertisement
Related to this article
The first-in-human study of the GalNAc-conjugated siRNA joins a fast-moving Stargardt pipeline as the FDA weighs the first potential approval for the disease.
Jayakrishna Ambati, MD, discusses phase 2 K8 findings in geographic atrophy, inflammasome targeting and K8 dosing and delivery.
R. Ross Lakhanpal, MD, FACS, Anu Patel, MD, and Yasha S. Modi, MD, MHS, point to cell replacement in geographic atrophy, care burden, and glycemic control.
The once-daily combination drop is approved by the FDA to treat presbyopia.
Katherine Talcott, MD, discusses phase 2 VERONA findings on the vorolanib intravitreal insert in previously treated DME
The half-life extended FcRn inhibitor showed a 74% peak reduction in IgG in healthy volunteers.
The agency concluded that GLP-1 receptor agonists carry a potential increased risk of the rare optic neuropathy and is adding it to the Warnings and Precautions section of every product's label.
Advertisement
Advertisement
Trending on Eye Care Network - Ophthalmology Times
1
FDA requires NAION warning across the GLP-1 receptor agonist class
2
City Therapeutics doses first participant in phase 1 trial of RNAi therapy CITY-RBP4 for Stargardt disease
3
VERONA: Katherine Talcott, MD, on early gains with a TKI insert in DME
4
Anti-VEGF switches for persistent fluid: A review of 3 clinical cases
5